<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241105171014
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241105171014" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 05 Nov 2024 22:10:15 +0000</lastbuilddate>
<pubDate>Tue, 05 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Advances in the treatment of hypertrophic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39498865/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 5:ehae710. doi: 10.1093/eurheartj/ehae710. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39498865/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39498865</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae710>10.1093/eurheartj/ehae710</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39498865</guid>
<pubDate>Tue, 05 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-11-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Advances in the treatment of hypertrophic cardiomyopathy</dc:title>
<dc:identifier>pmid:39498865</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae710</dc:identifier>
</item>
<item>
<title>Dendritic cell mineralocorticoid receptor controls blood pressure by regulating T helper 17 differentiation: role of the Plcβ1/4-Stat5-NF-κB pathway</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39498862/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Dendritic cell MR plays important roles in the pathogenesis of hypertension by regulating Th17 through Plcβ1/4-Stat5-NF-κB signalling, and blockade of DC MR is beneficial for treating hypertension.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 5:ehae670. doi: 10.1093/eurheartj/ehae670. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Dendritic cells (DCs) are closely related to blood pressure (BP) regulation. Mineralocorticoid receptor (MR) is an important drug target for antihypertensive treatment. However, the role of DC MR in the pathogenesis of hypertension has not been fully elucidated. This study aimed to determine the role of DC MR in BP regulation and to explore the mechanism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Renal biopsy and peripheral blood samples were collected from hypertensive patients (HTN) for immunostaining and flow cytometry. Dendritic cell MR knockout (DCMRKO) mice, DC MR overexpressing (DCMROV) mice, DCMROV/IL-17A knockout (DCMROV/IL-17AKO) mice and finerenone-treated C57BL/6 mice were infused with angiotensin II (Ang II) to establish hypertensive models. Western blotting, chromatin immunoprecipitation, co-immunoprecipitation, and in vivo DC depletion or adoptive transfer were used to delineate the functional importance of DC MR in hypertension development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Mineralocorticoid receptor antagonists (spironolactone and finerenone) suppressed DC aggregation and activation, as well as hypertension in HTN and mice. Compared with littermate control (LC) mice, dendritic cell MR knockout mice had strikingly decreased BPs and attenuated target organ damage after Ang II infusion. Flow cytometry showed that DC MR deficiency mitigated Ang II-induced DC activation and T helper 17 (Th17) cell differentiation. RNA sequencing revealed that MR-deficient DCs had elevated expression of Plcβ1 and Plcβ4, knockdown of which reversed the inhibitory effect of MR deficiency on DC activation and Th17 differentiation. Adoptive transfer of MR-deficient DCs protected Ang II-induced hypertension, whereas knockdown of Plcβ1/4 eliminated the protective effects. At the molecular level, MR negatively regulated Plcβ1/4, which recruited SHP-1 to inactivate of Stat5 activity, resulting in enhanced NF-κB activation and Th17 polarization. Furthermore, DCMROV mice manifested more elevated BPs and target organ damage than control mice after Ang II infusion, and these differences were abolished in DCMROV/IL-17AKO mice. Finally, MR antagonists decreased the aggregation of Th17 in HTN and mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Dendritic cell MR plays important roles in the pathogenesis of hypertension by regulating Th17 through Plcβ1/4-Stat5-NF-κB signalling, and blockade of DC MR is beneficial for treating hypertension.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39498862/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39498862</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae670>10.1093/eurheartj/ehae670</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39498862</guid>
<pubDate>Tue, 05 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yong-Li Wang</dc:creator>
<dc:creator>Hong Zhu</dc:creator>
<dc:creator>Yi-Tong Pan</dc:creator>
<dc:creator>Da Shang</dc:creator>
<dc:creator>Lin-Juan Du</dc:creator>
<dc:creator>Lan Bai</dc:creator>
<dc:creator>Shi-Wei Zhu</dc:creator>
<dc:creator>Wen-Zhen Lin</dc:creator>
<dc:creator>Xing-Yu Zhang</dc:creator>
<dc:creator>Hai-Xia Lu</dc:creator>
<dc:creator>Chao Bi</dc:creator>
<dc:creator>Yuan Liu</dc:creator>
<dc:creator>Yan Liu</dc:creator>
<dc:creator>Hui Xiao</dc:creator>
<dc:creator>You-Cun Qian</dc:creator>
<dc:creator>Bin Zhou</dc:creator>
<dc:creator>Ruo-Gu Li</dc:creator>
<dc:creator>Sheng-Zhong Duan</dc:creator>
<dc:date>2024-11-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dendritic cell mineralocorticoid receptor controls blood pressure by regulating T helper 17 differentiation: role of the Plcβ1/4-Stat5-NF-κB pathway</dc:title>
<dc:identifier>pmid:39498862</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae670</dc:identifier>
</item>
<item>
<title>Transseptal Transcatheter Valve-in-Valve Mitral Valve Implantation: Ready for Prime Time</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):1505-1507. doi: 10.1161/CIRCULATIONAHA.124.071666. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495840</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071666>10.1161/CIRCULATIONAHA.124.071666</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495840</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Marina Urena</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Transseptal Transcatheter Valve-in-Valve Mitral Valve Implantation: Ready for Prime Time</dc:title>
<dc:identifier>pmid:39495840</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071666</dc:identifier>
</item>
<item>
<title>Letter by Zhao et al Regarding Article, "Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):e348-e349. doi: 10.1161/CIRCULATIONAHA.124.071245. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495839</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071245>10.1161/CIRCULATIONAHA.124.071245</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495839</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jing Zhao</dc:creator>
<dc:creator>Qing-Liu Li</dc:creator>
<dc:creator>Peng-Zhou Hang</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhao et al Regarding Article, "Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth"</dc:title>
<dc:identifier>pmid:39495839</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071245</dc:identifier>
</item>
<item>
<title>The Cardiac Intensive Care Unit at Age 60</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495838/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):1481-1483. doi: 10.1161/CIRCULATIONAHA.124.070542. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495838/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495838</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070542>10.1161/CIRCULATIONAHA.124.070542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495838</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Erin A Bohula</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Cardiac Intensive Care Unit at Age 60</dc:title>
<dc:identifier>pmid:39495838</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070542</dc:identifier>
</item>
<item>
<title>A Day Like Every Other Day: 2024 Perioperative Guidelines and Their Clinical Impact</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495837/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):1484-1486. doi: 10.1161/CIRCULATIONAHA.124.071100. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495837/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495837</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071100>10.1161/CIRCULATIONAHA.124.071100</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495837</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Henry B Han</dc:creator>
<dc:creator>James B Froehlich</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Day Like Every Other Day: 2024 Perioperative Guidelines and Their Clinical Impact</dc:title>
<dc:identifier>pmid:39495837</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071100</dc:identifier>
</item>
<item>
<title>Treating Reproductive-Aged Women With Glucagon-Like Peptide-1 Receptor Agonists: What Are the Clinical Considerations?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495836/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):1487-1489. doi: 10.1161/CIRCULATIONAHA.124.070766. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495836/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495836</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070766>10.1161/CIRCULATIONAHA.124.070766</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495836</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Garima Sharma</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Treating Reproductive-Aged Women With Glucagon-Like Peptide-1 Receptor Agonists: What Are the Clinical Considerations?</dc:title>
<dc:identifier>pmid:39495836</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070766</dc:identifier>
</item>
<item>
<title>Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495835/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):1560-1562. doi: 10.1161/CIRCULATIONAHA.123.067470. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495835/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495835</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067470>10.1161/CIRCULATIONAHA.123.067470</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495835</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Kensey L Gosch</dc:creator>
<dc:creator>Chantal Dolan</dc:creator>
<dc:creator>Jennifer T Fine</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:creator>Sheila M Hegde</dc:creator>
<dc:creator>Jenny Lam</dc:creator>
<dc:creator>Amy J Sehnert</dc:creator>
<dc:creator>Sharon Cresci</dc:creator>
<dc:creator>Richard G Bach</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association of Echocardiographic Parameters and Health Status in Patients With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM</dc:title>
<dc:identifier>pmid:39495835</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067470</dc:identifier>
</item>
<item>
<title>Response by Caller et al to Letter Regarding Article, "Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):e350. doi: 10.1161/CIRCULATIONAHA.124.071538. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495834/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495834</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071538>10.1161/CIRCULATIONAHA.124.071538</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495834</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tal Caller</dc:creator>
<dc:creator>Crislyn D'Souza-Schorey</dc:creator>
<dc:creator>Nili Naftali-Shani</dc:creator>
<dc:creator>Jonathan Leor</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Caller et al to Letter Regarding Article, "Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth"</dc:title>
<dc:identifier>pmid:39495834</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071538</dc:identifier>
</item>
<item>
<title>Cardiovascular Care in Canada: Strengths, Challenges, and Opportunities For Improvement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 5;150(19):1490-1492. doi: 10.1161/CIRCULATIONAHA.124.070628. Epub 2024 Nov 4.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495833</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070628>10.1161/CIRCULATIONAHA.124.070628</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495833</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tauben Averbuch</dc:creator>
<dc:creator>Krista Stelkia</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Care in Canada: Strengths, Challenges, and Opportunities For Improvement</dc:title>
<dc:identifier>pmid:39495833</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070628</dc:identifier>
</item>
<item>
<title>Binge drinking and arrhythmias: a sobering message</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495219/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 4:ehae709. doi: 10.1093/eurheartj/ehae709. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495219/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495219</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae709>10.1093/eurheartj/ehae709</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495219</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Nicole Evans</dc:creator>
<dc:creator>Aleksandr Voskoboinik</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Binge drinking and arrhythmias: a sobering message</dc:title>
<dc:identifier>pmid:39495219</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae709</dc:identifier>
</item>
<item>
<title>Another piece in the puzzle of atrial fibrillation risk: clinical, genetic, and electrocardiogram-based artificial intelligence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39495215/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 4:ehae691. doi: 10.1093/eurheartj/ehae691. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39495215/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39495215</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae691>10.1093/eurheartj/ehae691</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39495215</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Shaan Khurshid</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Another piece in the puzzle of atrial fibrillation risk: clinical, genetic, and electrocardiogram-based artificial intelligence</dc:title>
<dc:identifier>pmid:39495215</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae691</dc:identifier>
</item>
<item>
<title>Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39492722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 4. doi: 10.1161/CIRCULATIONAHA.124.069556. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASCVD risk at different thresholds is not well defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A participant-level meta-analysis of 27 658 participants enrolled in 6 placebo-controlled statin trials was performed to assess the association of LDL-C and Lp(a) levels with risk of fatal or nonfatal coronary heart disease events, stroke, or any coronary or carotid revascularization (ASCVD). The multivariable-adjusted association between baseline Lp(a) level and ASCVD risk was modeled continuously using generalized additive models, and the association between baseline LDL-C level and ASCVD risk by baseline Lp(a) level by Cox proportional hazards models with random effects. The joint association between Lp(a) level and statin-achieved LDL-C level with ASCVD risk was evaluated using Cox proportional hazards models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with an Lp(a) level of 5 mg/dL, increasing levels of Lp(a) were log-linearly associated with ASCVD risk in statin- and placebo-treated patients. Among statin-treated individuals, those with Lp(a) level >;50 mg/dL (≈125 nmol/L) had increased risk across all quartiles of achieved LDL-C level and absolute change in LDL-C level. Even among those with the lowest quartile of achieved LDL-C level (3.1-77.0 mg/dL), those with Lp(a) level >;50 mg/dL had greater ASCVD risk (hazard ratio, 1.38 [95% CI, 1.06-1.79]) than those with Lp(a) level ≤50 mg/dL. The greatest risk was observed with both Lp(a) level >;50 mg/dL and LDL-C level in the fourth quartile (hazard ratio, 1.90 [95% CI, 1.46-2.48]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39492722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39492722</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069556>10.1161/CIRCULATIONAHA.124.069556</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39492722</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Harpreet S Bhatia</dc:creator>
<dc:creator>Simon Wandel</dc:creator>
<dc:creator>Peter Willeit</dc:creator>
<dc:creator>Anastasia Lesogor</dc:creator>
<dc:creator>Keith Bailey</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Paul Nestel</dc:creator>
<dc:creator>John Simes</dc:creator>
<dc:creator>Andrew Tonkin</dc:creator>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:creator>Helen Colhoun</dc:creator>
<dc:creator>Christoph Wanner</dc:creator>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis</dc:title>
<dc:identifier>pmid:39492722</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069556</dc:identifier>
</item>
<item>
<title>Kindlin-2 Phase Separation in Response to Flow Controls Vascular Stability</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39492718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Collectively, our study elucidates that mechanical force induces arginine methylation of Kindlin-2, thereby regulating vascular stability through its impact on Kindlin-2 LLPS. Targeting Kindlin-2 arginine methylation emerges as a promising hemodynamic-based strategy for treating vascular disorders and atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Nov 4. doi: 10.1161/CIRCRESAHA.124.324773. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atheroprotective shear stress preserves endothelial barrier function, while atheroprone shear stress enhances endothelial permeability. Yet, the underlying mechanisms through which distinct flow patterns regulate EC integrity remain to be clarified. This study aimed to investigate the involvement of Kindlin-2, a key component of focal adhesion and endothelial adherens junctions crucial for regulating endothelial cell (EC) integrity and vascular stability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Mouse models of atherosclerosis in EC-specific <i>Kindlin-2</i> knockout mice (<i>Kindlin-2</i><sup><i>iΔEC</i></sup>) were used to study the role of Kindlin-2 in atherogenesis. Pulsatile shear (2±4 dynes/cm<sup>2</sup>) or oscillatory shear (0.5±4 dynes/cm<sup>2</sup>) were applied to culture ECs. Live-cell imaging, fluorescence recovery after photobleaching assay, and optoDroplet assay were used to study the liquid-liquid phase separation (LLPS) of Kindlin-2. Co-immunoprecipitation, mutagenesis, proximity ligation assay, and transendothelial electrical resistance assay were used to explore the underlying mechanism of flow-regulated Kindlin-2 function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that Kindlin-2 localization is altered under different flow patterns. <i>Kindlin-2</i><sup><i>iΔEC</i></sup> mice showed heightened vascular permeability. <i>Kindlin-2</i><sup><i>iΔEC</i></sup> were bred onto <i>ApoE</i><sup><i>-/-</i></sup> mice to generate <i>Kindlin-2</i><sup><i>iΔEC</i></sup>; <i>ApoE</i><sup><i>-</i></sup><sup><i>/-</i></sup> mice, which displayed a significant increase in atherosclerosis lesions. In vitro data showed that in ECs, Kindlin-2 underwent LLPS, a critical process for proper focal adhesion assembly, maturation, and junction formation. Mass spectrometry analysis revealed that oscillatory shear increased arginine methylation of Kindlin-2, catalyzed by PRMT5 (protein arginine methyltransferase 5). Functionally, arginine hypermethylation inhibits Kindlin-2 LLPS, impairing focal adhesion assembly and junction maturation. Notably, we identified R290 of Kindlin-2 as a crucial residue for LLPS and a key site for arginine methylation. Finally, pharmacologically inhibiting arginine methylation reduces EC activation and plaque formation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Collectively, our study elucidates that mechanical force induces arginine methylation of Kindlin-2, thereby regulating vascular stability through its impact on Kindlin-2 LLPS. Targeting Kindlin-2 arginine methylation emerges as a promising hemodynamic-based strategy for treating vascular disorders and atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02783300.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39492718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39492718</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324773>10.1161/CIRCRESAHA.124.324773</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39492718</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Nina Ma</dc:creator>
<dc:creator>Fangfang Wu</dc:creator>
<dc:creator>Jiayu Liu</dc:creator>
<dc:creator>Ziru Wu</dc:creator>
<dc:creator>Lu Wang</dc:creator>
<dc:creator>Bochuan Li</dc:creator>
<dc:creator>Yuming Liu</dc:creator>
<dc:creator>Xue Dong</dc:creator>
<dc:creator>Junhao Hu</dc:creator>
<dc:creator>Xi Fang</dc:creator>
<dc:creator>Heng Zhang</dc:creator>
<dc:creator>Ding Ai</dc:creator>
<dc:creator>Jing Zhou</dc:creator>
<dc:creator>Xiaohong Wang</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Kindlin-2 Phase Separation in Response to Flow Controls Vascular Stability</dc:title>
<dc:identifier>pmid:39492718</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324773</dc:identifier>
</item>
<item>
<title>Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39492713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Multicomponent activity intervention during and after allo-SCT is beneficial for preserving patient cardiorespiratory fitness and exercise cardiac function. These results may have important implications for cardiovascular morbidity and mortality after allo-SCT.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 4. doi: 10.1161/CIRCULATIONAHA.124.070709. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be complicated by cardiac dysfunction and exercise intolerance impacting quality of life and longevity. We conducted a randomized controlled trial testing whether a multicomponent activity intervention could attenuate reductions in cardiorespiratory fitness and exercise cardiac function (co-primary end points) in adults undergoing allo-SCT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Sixty-two adults scheduled for allo-SCT were randomized to a 4-month activity program (n=30) or usual care (UC; n=32). Activity comprised multicomponent exercise training (3 days/week) and sedentary time reduction (≥30 min/day) program and was delivered throughout hospitalization (≈4 weeks) and for 12 weeks after discharge. Physiological assessments conducted before admission and at 12 weeks after discharge included cardiopulmonary exercise testing to quantify peak oxygen uptake ([Formula: see text]), exercise cardiac magnetic resonance imaging for peak cardiac volume (CI<sub>peak</sub>) and stroke volume (SVI<sub>peak</sub>) index, echocardiography-derived left ventricular ejection fraction and global longitudinal strain, and cardiac biomarkers (cTn-I [troponin-I] and BNP [B-type natriuretic peptide]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Fifty-two participants (84%) completed follow-up (25 activity and 27 UC); median (interquartile range [IQR]) adherence to the activity program was 74% (41-96%). There was a marked decline in [Formula: see text] in the UC program (-3.4 mL‧kg<sup>-1</sup>‧min<sup>-1</sup> [95% CI, -4.9 to -1.8]) that was attenuated with activity (-0.9 mL‧kg<sup>-1‧</sup>min<sup>-1</sup> [95% CI, -2.5 to 0.8]; interaction <i>P</i>=0.029). Activity preserved exercise cardiac function, with preservation of CI<sub>peak</sub> (0.30 L‧min<sup>-1</sup>‧m<sup>-</sup><sup>2</sup> [95% CI, -0.34 to 0.41]) and SVI<sub>peak</sub> (0.6 mL/m<sup>2</sup> [95% CI, -1.3 to 2.5]), both of which declined with UC (CI<sub>peak</sub>, -0.68 L‧min<sup>-1</sup>‧m<sup>-</sup><sup>2</sup> [95% CI, -1.3 to -0.32]; interaction <i>P</i>=0.008; SVI<sub>peak</sub>, -2.7 mL/m<sup>2</sup> [95% CI, -4.6 to -0.9]; interaction <i>P=</i>0.014). There were no treatment effects of activity on cardiac biomarkers or echocardiographic indices.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Multicomponent activity intervention during and after allo-SCT is beneficial for preserving patient cardiorespiratory fitness and exercise cardiac function. These results may have important implications for cardiovascular morbidity and mortality after allo-SCT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://anzctr.org.au/; Unique identifier: ACTRN12619000741189.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39492713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39492713</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070709>10.1161/CIRCULATIONAHA.124.070709</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39492713</guid>
<pubDate>Mon, 04 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Hayley T Dillon</dc:creator>
<dc:creator>Nicholas J Saner</dc:creator>
<dc:creator>Tegan Ilsley</dc:creator>
<dc:creator>David S Kliman</dc:creator>
<dc:creator>Stephen J Foulkes</dc:creator>
<dc:creator>Christian J Brakenridge</dc:creator>
<dc:creator>Andrew Spencer</dc:creator>
<dc:creator>Sharon Avery</dc:creator>
<dc:creator>Piet Claus</dc:creator>
<dc:creator>David W Dunstan</dc:creator>
<dc:creator>Robin M Daly</dc:creator>
<dc:creator>Steve F Fraser</dc:creator>
<dc:creator>Neville Owen</dc:creator>
<dc:creator>Brigid M Lynch</dc:creator>
<dc:creator>Bronwyn A Kingwell</dc:creator>
<dc:creator>Andre La Gerche</dc:creator>
<dc:creator>Erin J Howden</dc:creator>
<dc:date>2024-11-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial</dc:title>
<dc:identifier>pmid:39492713</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070709</dc:identifier>
</item>
<item>
<title>Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39490700/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In FINEARTS-HF, a population at low risk of adverse kidney outcomes, finerenone did not significantly modify the kidney composite outcomes. Finerenone led to a greater reduction in initial eGFR, but did not result in a significant difference in chronic eGFR slope, vs. placebo. Finerenone led to early and sustained reductions in albuminuria and reduced the risk of new-onset micro- and macroalbuminuria.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)10252-5. doi: 10.1016/j.jacc.2024.10.091. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Finerenone has kidney protective effects in patients with chronic kidney disease (CKD) with type 2 diabetes, but effects on kidney outcomes in patients with heart failure (HF) with and without diabetes and/or CKD are not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Examine the effects of finerenone on kidney outcomes in FINEARTS-HF, a randomized trial of finerenone vs. placebo among patients with HF with mildly reduced or preserved ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We explored the effects of finerenone on the secondary outcome of a sustained ≥50% eGFR decline or kidney failure (sustained eGFR decline &lt;15 mL/min/1.73 m<sup>2</sup>; initiation of maintenance dialysis; renal transplant). In this prespecified analysis, we also report effects of finerenone on: 1) sustained ≥57% eGFR decline or kidney failure; 2) eGFR slope; 3) changes in urine albumin/creatinine ratio (UACR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6,001 participants, mean baseline eGFR was 62 ±20mL/min/1.73m<sup>2</sup>; 48% had eGFR &lt;60mL/min/1.73m<sup>2</sup>. Overall, 5,797 had baseline UACR data (median 18 [7,67]mg/g). Over 2.6 years median follow-up, the incidence of the composite kidney outcome (≥50% eGFR decline or kidney failure) was numerically, but non-significantly, higher for finerenone vs. placebo (75 vs. 55 events; HR 1.33; 95%CI 0.94, 1.89). Similar results were observed for the composite of ≥57% eGFR decline or kidney failure (41 vs. 31 events; HR 1.28; 95%CI 0.80, 2.05), though the overall event frequency was relatively low. During the first 3 months, finerenone led to an acute decline in eGFR of -2.9 mL/min/1.73m<sup>2</sup> (95%CI -3.4, -2.4) but did not alter chronic (from 3 months) eGFR slope (+0.2 mL/min/1.73m<sup>2</sup>/year; 95%CI -0.1, +0.4), vs. placebo. The difference in total slope was -0.7 (95%CI -0.9 to -0.4) mL/min/1.73 m<sup>2</sup>/year. Finerenone reduced UACR by 30% (95%CI 25%, 34%) over 6 months vs. placebo, an effect that persisted throughout follow-up. Finerenone reduced the risk of new-onset of micro- and macroalbuminuria by 24% (HR 0.76; 95%CI 0.68, 0.83) and 38% (HR 0.62; 95%CI 0.53, 0.73), respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In FINEARTS-HF, a population at low risk of adverse kidney outcomes, finerenone did not significantly modify the kidney composite outcomes. Finerenone led to a greater reduction in initial eGFR, but did not result in a significant difference in chronic eGFR slope, vs. placebo. Finerenone led to early and sustained reductions in albuminuria and reduced the risk of new-onset micro- and macroalbuminuria.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39490700/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39490700</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.091>10.1016/j.jacc.2024.10.091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39490700</guid>
<pubDate>Sun, 03 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Meike Brinker</dc:creator>
<dc:creator>Robert Perkins</dc:creator>
<dc:creator>Markus F Scheerer</dc:creator>
<dc:creator>Patrick Schloemer</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-11-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial</dc:title>
<dc:identifier>pmid:39490700</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.091</dc:identifier>
</item>
<item>
<title>Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39488207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>Targeted protein degradation (TPD) utilizes molecular glues or proteolysis-targeting chimeras (PROTACs) to eliminate disease-causing proteins by promoting their interaction with E3 ubiquitin ligases. Current TPD approaches are limited by reliance on a small number of constitutively active E3 ubiquitin ligases. Here, we report that (S)-ACE-OH, a metabolite of the antipsychotic drug acepromazine, acts as a molecular glue to induce an interaction between the E3 ubiquitin ligase TRIM21 and the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 30:S0092-8674(24)01197-8. doi: 10.1016/j.cell.2024.10.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Targeted protein degradation (TPD) utilizes molecular glues or proteolysis-targeting chimeras (PROTACs) to eliminate disease-causing proteins by promoting their interaction with E3 ubiquitin ligases. Current TPD approaches are limited by reliance on a small number of constitutively active E3 ubiquitin ligases. Here, we report that (S)-ACE-OH, a metabolite of the antipsychotic drug acepromazine, acts as a molecular glue to induce an interaction between the E3 ubiquitin ligase TRIM21 and the nucleoporin NUP98, leading to the degradation of nuclear pore proteins and disruption of nucleocytoplasmic trafficking. Functionalization of acepromazine into PROTACs enabled selective degradation of multimeric proteins, such as those within biomolecular condensates, while sparing monomeric proteins. This selectivity is consistent with the requirement of substrate-induced clustering for TRIM21 activation. As aberrant protein assemblies cause diseases such as autoimmunity, neurodegeneration, and cancer, our findings highlight the potential of TRIM21-based multimer-selective degraders as a strategy to tackle the direct causes of these diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39488207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39488207</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.015>10.1016/j.cell.2024.10.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39488207</guid>
<pubDate>Sat, 02 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Panrui Lu</dc:creator>
<dc:creator>Yalong Cheng</dc:creator>
<dc:creator>Lei Xue</dc:creator>
<dc:creator>Xintong Ren</dc:creator>
<dc:creator>Xilong Xu</dc:creator>
<dc:creator>Chenglong Chen</dc:creator>
<dc:creator>Longzhi Cao</dc:creator>
<dc:creator>Jiaojiao Li</dc:creator>
<dc:creator>Qingcui Wu</dc:creator>
<dc:creator>Shan Sun</dc:creator>
<dc:creator>Junjie Hou</dc:creator>
<dc:creator>Wei Jia</dc:creator>
<dc:creator>Wei Wang</dc:creator>
<dc:creator>Yan Ma</dc:creator>
<dc:creator>Zhaodi Jiang</dc:creator>
<dc:creator>Chao Li</dc:creator>
<dc:creator>Xiangbing Qi</dc:creator>
<dc:creator>Niu Huang</dc:creator>
<dc:creator>Ting Han</dc:creator>
<dc:date>2024-11-02</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders</dc:title>
<dc:identifier>pmid:39488207</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.015</dc:identifier>
</item>
<item>
<title>Beyond Prognosis: The Vital Role of Quality of Life after Transcatheter Tricuspid Valve Replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39486558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)10055-1. doi: 10.1016/j.jacc.2024.10.087. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39486558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39486558</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.087>10.1016/j.jacc.2024.10.087</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39486558</guid>
<pubDate>Fri, 01 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Domenico Angellotti</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2024-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Beyond Prognosis: The Vital Role of Quality of Life after Transcatheter Tricuspid Valve Replacement</dc:title>
<dc:identifier>pmid:39486558</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.087</dc:identifier>
</item>
<item>
<title>Advances in Transcatheter Tricuspid Valve Interventions-Implications for Health Policy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39486557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)10057-5. doi: 10.1016/j.jacc.2024.10.089. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39486557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39486557</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.089>10.1016/j.jacc.2024.10.089</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39486557</guid>
<pubDate>Fri, 01 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Kushal T Kadakia</dc:creator>
<dc:creator>Sanket S Dhruva</dc:creator>
<dc:date>2024-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Advances in Transcatheter Tricuspid Valve Interventions-Implications for Health Policy</dc:title>
<dc:identifier>pmid:39486557</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.089</dc:identifier>
</item>
<item>
<title>Transcatheter Interventions in Tricuspid Regurgitation: Shifting the focus beyond Quantity of Life to Quality of Life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39486556/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 18:S0735-1097(24)10053-8. doi: 10.1016/j.jacc.2024.10.085. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39486556/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39486556</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.085>10.1016/j.jacc.2024.10.085</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39486556</guid>
<pubDate>Fri, 01 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Aakriti Gupta</dc:creator>
<dc:creator>Celina Yong</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:date>2024-11-01</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Interventions in Tricuspid Regurgitation: Shifting the focus beyond Quantity of Life to Quality of Life</dc:title>
<dc:identifier>pmid:39486556</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.085</dc:identifier>
</item>
<item>
<title>Empowering biomedical discovery with AI agents</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39486399/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241105171014&amp;v=2.18.0.post9+e462414
      <description>We envision "AI scientists" as systems capable of skeptical learning and reasoning that empower biomedical research through collaborative agents that integrate AI models and biomedical tools with experimental platforms. Rather than taking humans out of the discovery process, biomedical AI agents combine human creativity and expertise with AI's ability to analyze large datasets, navigate hypothesis spaces, and execute repetitive tasks. AI agents are poised to be proficient in various tasks,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 31;187(22):6125-6151. doi: 10.1016/j.cell.2024.09.022.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We envision "AI scientists" as systems capable of skeptical learning and reasoning that empower biomedical research through collaborative agents that integrate AI models and biomedical tools with experimental platforms. Rather than taking humans out of the discovery process, biomedical AI agents combine human creativity and expertise with AI's ability to analyze large datasets, navigate hypothesis spaces, and execute repetitive tasks. AI agents are poised to be proficient in various tasks, planning discovery workflows and performing self-assessment to identify and mitigate gaps in their knowledge. These agents use large language models and generative models to feature structured memory for continual learning and use machine learning tools to incorporate scientific knowledge, biological principles, and theories. AI agents can impact areas ranging from virtual cell simulation, programmable control of phenotypes, and the design of cellular circuits to developing new therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39486399/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241105171014&v=2.18.0.post9+e462414">39486399</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.022>10.1016/j.cell.2024.09.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39486399</guid>
<pubDate>Fri, 01 Nov 2024 06:00:00 -0400</pubDate>
<dc:creator>Shanghua Gao</dc:creator>
<dc:creator>Ada Fang</dc:creator>
<dc:creator>Yepeng Huang</dc:creator>
<dc:creator>Valentina Giunchiglia</dc:creator>
<dc:creator>Ayush Noori</dc:creator>
<dc:creator>Jonathan Richard Schwarz</dc:creator>
<dc:creator>Yasha Ektefaie</dc:creator>
<dc:creator>Jovana Kondic</dc:creator>
<dc:creator>Marinka Zitnik</dc:creator>
<dc:date>2024-11-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Empowering biomedical discovery with AI agents</dc:title>
<dc:identifier>pmid:39486399</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.022</dc:identifier>
</item>





























</channel>
</rss>